Quick Facts

• Therapeutic Domain: Bacterial Infections
• Primary Uses: May address infections of the urinary, gastrointestinal, and respiratory tracts.
• General Benefit: Used to manage infections caused by susceptible microorganisms.

Intertrim is a combination product intended for use in managing certain bacterial infections. The product, which contains trimethoprim and a sulfonamide component (such as sulfamethoxazole or sulfadiazine, depending on the formulation), is indicated for the treatment of infections caused by susceptible strains of bacteria.

Commonly addressed conditions may include infections in the gastrointestinal, respiratory, and urinary systems. The medicine may be utilized to help resolve issues arising from Gram-positive and Gram-negative organisms, such as E. coli, Salmonella, and Staphylococcus species. Due to its antibacterial activity, the combination supports the clearance of infections caused by sensitive bacteria. This approach to treatment aims to assist with the recovery process in affected systems.

Regulatory References

1. NIH MedlinePlus guidance

Eligibility Scope

The following rules reflect the official population eligibility and non-eligibility for this medicine, which is a combination antibiotic (Trimethoprim/Sulfonamide), as documented in regulatory labeling.

Classification	Eligible or Prohibited Population
Allowed	Adults and pediatric patients 2 months of age and older with normal organ function.
Contraindicated	Patients with a known hypersensitivity to trimethoprim or sulfonamides.
Contraindicated	Pediatric patients less than 2 months of age.
Contraindicated	Patients with documented megaloblastic anemia due to folate deficiency.
Contraindicated	Patients with marked hepatic damage or severe renal insufficiency (Creatinine Clearance < 15 mL/min).
Contraindicated	Pregnant patients at term and nursing mothers.

Condition-Based and Age Restrictions

• Organ Function Status: Use is strictly forbidden for individuals with severe hepatic damage or severe renal insufficiency. Patients with moderate renal impairment (CrCl 15 to 30 mL/min) are subject to conditional use, which necessitates an official dose adjustment.
• Reproductive Status: The medicine is contraindicated for use in nursing mothers and pregnant patients at term due to potential risks, and is generally not recommended throughout pregnancy.
• Special Populations: The use of this medicine requires caution and monitoring in the older adult population, as this group may be at higher risk for severe reactions, including issues related to folate levels.

This eligibility profile is entirely structured around avoiding the use in populations where the medicine is officially listed as dangerous or ineffective, based on age, physiological status, or history of hypersensitivity reactions.

Interactions with other medicines and products

The interaction profile for Intertrim is defined by several documented pharmacokinetic and pharmacodynamic mechanisms as outlined in official regulatory sources. These documented interaction patterns result in specific prescribing constraints.

Contraindicated Combinations

Co-administration with Dofetilide is formally prohibited because the combination significantly increases Dofetilide plasma concentrations, raising the documented risk of life-threatening ventricular arrhythmias. Similarly, use with high-dose Methotrexate is strictly contraindicated due to the potential for increased drug exposure and severe toxicity, including bone marrow suppression.

Pharmacokinetic Interactions

Intertrim is documented to alter the clearance of several co-administered medicines. The sulfonamide component is an established inhibitor of the CYP2C9 enzyme, which can increase the plasma concentration of substrates like Phenytoin and potentiate the anticoagulant effect of Warfarin. Additionally, the trimethoprim component inhibits renal tubular secretion (cation transport), resulting in increased systemic exposure of agents such as Lamivudine and Procainamide.

Pharmacodynamic Interactions and Population Notes

Co-administration with Potassium-Elevating Agents (e.g., ACE Inhibitors, ARBs, and Potassium-Sparing Diuretics) is associated with an additive pharmacodynamic effect, resulting in a documented risk of severe hyperkalemia. Regulatory documents note that this risk is specifically heightened in elderly patients. Separately, Folic Acid supplements may antagonize Intertrim’s antifolate action, potentially reducing its documented antimicrobial effectiveness.

Sequential Enzyme Inhibition (Targeting DHPS and DHFR)

Intertrim's action is based on a synergistic double blockade of the bacterial folic acid synthesis pathway, a process essential for microbial survival. This dual action is characterized by enhanced affinity for bacterial enzymes. The sulfonamide component, Sulfadiazine, competitively inhibits the Dihydropteroate Synthetase ( DHPS) enzyme , acting as a false precursor. Subsequently, Trimethoprim selectively inhibits Dihydrofolate Reductase ( DHFR), which prevents the remaining precursors from being converted into the crucial co-factor, Tetrahydrofolate ( THF). This coordinated, two-step interference leads to a severe depletion of THF stores.

Halting Microbial Genetic Material Synthesis

The resultant lack of THF directly shuts down the synthesis of essential building blocks like purines and pyrimidines, which are needed for bacterial DNA and RNA replication. This failure to produce or repair genetic material rapidly halts all microbial proliferation and results in a bactericidal (cell-killing) physiological effect.

Mechanistic Constraints and Antagonism

The drug's mechanism is constrained by biological factors, including the microbe's ability to develop enzyme-based resistance or, externally, by the presence of high concentrations of the DHPS substrate, p-aminobenzoic acid ( PABA). The PABA in environments like necrotic or purulent tissue can override the action of Sulfadiazine, reducing the overall synergistic effect.

Intertrim, a combination of sulfamethoxazole and trimethoprim, is used in the treatment of various bacterial infections, including urinary tract infections, acute exacerbations of chronic bronchitis, and traveler's diarrhea. The specific dosage and duration of treatment are determined by a healthcare provider based on the type and severity of the infection, as well as the patient's renal function and age.

General Administration

• Intertrim tablets should be taken exactly as directed by a healthcare professional. Do not take more or less than the prescribed amount, or take it for a longer or shorter duration.
• The medication can be taken without regard to meals. However, it is important to take it with a full glass of water (at least 8 ounces).
• Maintaining adequate fluid intake throughout the treatment period is generally recommended to help prevent the formation of crystals in the urine (crystalluria).

Essential Patient Instructions

Action	Instruction
Do not stop early	Continue taking the medication for the full prescribed course of treatment, even if symptoms begin to improve quickly. Discontinuing too soon may result in the infection not being fully treated and could contribute to the development of antibiotic resistance.
Missed Dose	Take the missed dose as soon as you remember. If it is almost time for the next scheduled dose, skip the missed dose and resume your regular dosing schedule. Do not double the dose to make up for a missed one.
Storage	Store tablets at room temperature (20°C to 25°C or 68°F to 77°F) and keep them out of reach of children.

Research Evidence / Overview of Studies for Intertrim

Intertrim is a drug combination that was studied for various bacterial infections. The research studies help show what has been observed so far in specific populations and under defined study conditions. These findings describe group patterns, not personal outcomes, and evidence highlights what is known—and what is still uncertain.

---

Evidence for Use in Urinary Tract Infections (UTIs)

Research exploring the combination’s use in UTIs includes numerous Randomized Controlled Trials (RCTs) and subsequent systematic reviews. The research primarily evaluated adults and children (typically those older than two months) who presented with UTIs. In these trials, researchers monitored outcomes related to systemic or functional imbalance, such as the status of patient-reported symptoms, and measured microbiological outcomes. The applicability of findings is constrained by the need to continuously monitor local trends in bacterial resistance, which may vary by location.

---

Evidence for Use in Respiratory Tract Infections

Research was studied for this combination in various respiratory conditions. Controlled trials explored its use in adults during acute exacerbations of chronic lung conditions. Specialized research, including meta-analyses, was conducted in immunocompromised individuals, primarily focusing on protocols for Pneumocystis Jirovecii Pneumonia (PJP/PCP) treatment and prevention. Data show patterns related to how patients fared during these specific infectious episodes, with PJP/PCP studies monitoring survival-related findings.

---

Long-Term Studies and Follow-up Duration

Research was evaluated in studies where follow-up durations were limited (e.g., 5 to 14 days) for acute treatment. However, the combination was observed in studies that tracked prevention protocols, such as for recurrent UTIs and PJP/PCP, where observation periods may extend over months or years. This research helps contribute to the broader evidence landscape regarding recurrence patterns, but there is limited information for long-term outcomes regarding the general health status of participants far beyond the study protocol window.

---

What Is Still Uncertain About Intertrim’s Research Base

The evidence highlights what is known—and what is still uncertain about this combination. A key area where certainty remains low involves predicting the combination’s relevance to any given person or region, as data show patterns related to how bacterial resistance limits measured relevance. Furthermore, data are still emerging in highly specific patient subgroups, meaning continued monitoring and updated studies are required.

Key Studies & References Sulfamethoxazole and Trimethoprim: NIH MedlinePlus guidance (NBK513232)

Common questions about Intertrim (FAQ)

Q: What is Intertrim?

A: Intertrim is the brand name for the drug trimethoprim, an antibiotic used to treat various bacterial infections, including urinary tract infections (UTIs), middle ear infections (otitis media), and specific types of pneumonia. It works by interfering with the bacteria's ability to produce folic acid, which is essential for their growth and multiplication.

Q: How should I take Intertrim?

A: Intertrim is typically taken by mouth as a tablet or liquid suspension. The way you take it will depend on the infection being treated and your health condition. Follow your prescriber's instructions exactly.

• Swallow tablets whole with a full glass of water.
• If using the liquid suspension, shake it well before each use and measure the dose accurately with a marked spoon or device.
• You can usually take Intertrim with or without food.
• Take the medicine at evenly spaced times to keep a steady amount in your body.
• Do not stop taking Intertrim until you finish the full prescribed course, even if your symptoms improve, to ensure the infection is completely cleared.

Q: What are the common side effects of Intertrim?

A: The most common side effects are generally mild and may include:

• Nausea or vomiting
• Loss of appetite
• Diarrhea
• Skin rash or itching

Contact your healthcare provider if these symptoms are severe or do not go away. They can help manage these reactions.

Q: Can Intertrim be taken during pregnancy?

A: Intertrim may pose risks if taken during pregnancy, especially in the first trimester, as it can interfere with the body's use of folate. If you are pregnant or planning to become pregnant, you must inform your healthcare provider. They will weigh the benefits of treatment against the potential risks to the developing fetus and decide if Intertrim is the safest option, or if an alternative antibiotic should be used.

Q: Does Intertrim interact with any other medications?

A: Yes, Intertrim can interact with several other medications. These interactions can change how Intertrim or the other drug works, and may increase the risk of side effects. Key interactions include:

• Methotrexate: Taking Intertrim with this drug can increase the risk of blood problems.
• Warfarin (and other blood thinners): Intertrim may increase the effect of these drugs, raising the risk of bleeding.
• Potassium-sparing diuretics (water pills):
  • Taking Intertrim with these can lead to higher-than-normal potassium levels in the blood (hyperkalemia).

Always provide your healthcare provider with a complete list of all medications, vitamins, and herbal supplements you are taking before starting Intertrim.

How to Store and Dispose of Intertrim Solution for Injection

Official regulatory information outlines specific rules for maintaining product quality and ensuring safe disposal.

Storage and Handling Requirements

• Contamination Prevention: You must avoid the introduction of contamination when using the Intertrim solution.
• Visual Stability Check: The regulatory documents link storage integrity to visual checks. If the product shows apparent growth or discolouration, it must be discarded to ensure stability and safety.

Disposal Requirements

• Pharmaceutical Waste Mandate: Unused product and waste materials, including empty containers, must be disposed of as pharmaceutical waste.
• Regulatory Compliance: Disposal must be completed in accordance with current practice and all applicable national waste disposal regulations for medicinal products. This generally requires avoiding disposal in household trash or wastewater systems.

This information is based strictly on the official regulatory labeling and does not constitute medical advice or administration instructions.